Heinemeyer G, Link J, Weber W, Meschede V, Roots I
Institut für Klinische Pharmakologie, Freie Universität Berlin, Federal Republic of Germany.
Intensive Care Med. 1990;16(7):448-53. doi: 10.1007/BF01711224.
Serum concentrations of ceftriaxone (RocephinTM), a third generation cephalosporin, were monitored in 5 operative intensive care patients suffering from acute renal failure (ARF) and compared to those of 7 patients without renal disturbance. For a period of 7 days, a fixed dose of 2 g/day was given by a 15 min infusion. Pharmacokinetic parameters were calculated by fitting all serum and urine data measured over the period of treatment. Ceftriaxone free fraction was measured on days 2 and 7. There was no evidence for an intraindividual change in ceftriaxone-clearance during the observation period. Ceftriaxone renal clearance was closely dependent on creatinine clearance according to a linear regression expressed by Clren = 0.14 Clcrea + 2.2 (r = 0.951, p less than 0.0001). Total clearance was also associated with creatinine clearance: Cltot = 0.19 Clcrea + 8.2 (r = 0.964, p less than 0.0001). Related to the free fraction, renal clearance was in the range of the glomerular filtration rate. Non-renal clearance was strongly decreased when related to the free fraction indicating that biliary excretion is also impaired in patients with acute renal failure. Obviously no compensatory increase in hepatic ceftriaxone clearance takes place. It is concluded that elimination of ceftriaxone may be strongly impaired during acute renal failure in surgical intensive care patients and that dosage should be restricted according to degree of the impairment of creatinine clearance.
对5例患有急性肾衰竭(ARF)的外科重症监护患者监测了第三代头孢菌素头孢曲松(罗氏芬TM)的血清浓度,并与7例无肾脏功能障碍的患者进行了比较。在7天的时间里,通过15分钟输注给予固定剂量2g/天。通过拟合治疗期间测得的所有血清和尿液数据计算药代动力学参数。在第2天和第7天测量头孢曲松的游离分数。在观察期内没有证据表明头孢曲松清除率存在个体内变化。根据Clren = 0.14 Clcrea + 2.2表示的线性回归,头孢曲松的肾脏清除率与肌酐清除率密切相关(r = 0.951,p小于0.0001)。总清除率也与肌酐清除率相关:Cltot = 0.19 Clcrea + 8.2(r = 0.964,p小于0.0001)。与游离分数相关,肾脏清除率在肾小球滤过率范围内。当与游离分数相关时,非肾脏清除率大幅降低,这表明急性肾衰竭患者的胆汁排泄也受损。显然肝脏对头孢曲松的清除率没有代偿性增加。结论是,在外科重症监护患者的急性肾衰竭期间,头孢曲松的清除可能会严重受损,并且应根据肌酐清除率的受损程度限制剂量。